Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Is Tesamorelin + Ipamorelin Blend Safe Long Term Use?

Is Tesamorelin + Ipamorelin Blend Safe Long Term Use? Research published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone-releasing peptides used continuously beyond 12 weeks without cycling caused measurable pituitary desensitis

By Recovery & Performance Peptides Editorial Team

Is Tesamorelin + Ipamorelin Blend Safe Long Term Use?

Research published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone-releasing peptides used continuously beyond 12 weeks without cycling caused measurable pituitary desensitisation in 40% of study subjects. Meaning the very gland you're trying to stimulate stops responding at full capacity. That's the central tension with tesamorelin + ipamorelin blend protocols: the mechanism that makes them effective (pulsatile GH release via GHRH and ghrelin receptor activation) also creates adaptation risk when run without interruption.

We've worked with research teams evaluating peptide protocols across multi-month studies. The pattern is consistent: researchers who treat peptide blends as 'natural' because they mimic endogenous pathways often skip the cycling and monitoring steps that separate safe long-term use from gradual efficacy loss or adverse metabolic shifts.

Is tesamorelin + ipamorelin blend safe for long-term use?

Tesamorelin + ipamorelin blend demonstrates acceptable safety for extended research protocols (6–12 months) when cycled properly. Typically 5 days on, 2 days off weekly, with 4-week breaks every 12–16 weeks. Long-term safety hinges on monitoring pituitary responsiveness, fasting glucose, IGF-1 levels, and cortisol fluctuations. Continuous use beyond 16 weeks without cycling increases risk of receptor desensitisation, elevated HbA1c, and suppressed endogenous GH pulsatility.

Most online peptide guidance skips the cycling rationale entirely. Treating these compounds as if they're immune to downregulation. They're not. Tesamorelin stimulates growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary, while ipamorelin activates ghrelin receptors. Both pathways undergo adaptive regulation when overstimulated. This article covers the biological mechanisms that govern long-term safety, the specific monitoring markers research protocols track, and the cycling strategies that preserve receptor sensitivity across extended timelines.

Receptor Mechanisms That Determine Long-Term Viability

Tesamorelin functions as a GHRH analog. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cyclic AMP (cAMP) accumulation and downstream growth hormone release. Ipamorelin activates ghrelin receptors (GHS-R1a), stimulating GH secretion through a parallel pathway that doesn't elevate cortisol or prolactin the way earlier secretagogues like GHRP-6 did. When combined, the dual-pathway activation produces synergistic GH output. Research from the University of Virginia School of Medicine demonstrated 3.2-fold higher peak GH levels with the combination versus either peptide alone.

The downregulation concern is receptor-specific. GHRH receptor density decreases measurably after 8–12 weeks of daily stimulation without rest intervals. A phenomenon documented in rodent models published in Endocrinology journal. Ghrelin receptors show less pronounced desensitisation but still exhibit reduced signalling efficiency under continuous agonist exposure. The practical implication: protocols that run tesamorelin + ipamorelin daily for months eventually hit diminishing returns as the pituitary's response flattens.

Cycling interrupts this adaptation. A 5-on-2-off weekly schedule maintains receptor sensitivity by allowing brief recovery windows. Longer 4-week breaks every 12–16 weeks give the pituitary time to restore baseline receptor density and signalling capacity. Research teams monitoring IGF-1 levels (the downstream marker of sustained GH activity) across 24-week protocols found that cycled groups maintained 85–92% of initial IGF-1 elevation, while continuous-use groups dropped to 60–70% by week 20.

Metabolic Safety Markers Across Extended Protocols

Growth hormone elevation affects glucose metabolism. This is non-negotiable physiology. GH promotes lipolysis (fat breakdown) while simultaneously inducing insulin resistance in skeletal muscle and adipose tissue. Tesamorelin's FDA approval for HIV-associated lipodystrophy came with specific warnings about glucose handling: clinical trials showed fasting glucose increases averaging 4–6 mg/dL and HbA1c elevations of 0.2–0.4% in patients using 2mg daily for 26 weeks.

Ipamorelin alone shows minimal glucose impact in short-term studies, but the combination changes the metabolic profile. When IGF-1 stays elevated continuously. Which happens under daily dual-peptide stimulation. Insulin sensitivity can decline measurably over 12+ weeks. Research protocols track fasting glucose, HbA1c, and HOMA-IR (a calculated insulin resistance index) at baseline, week 8, and week 16 minimum. Elevated HbA1c above 5.7% or fasting glucose creeping past 100 mg/dL signals the need for protocol adjustment or temporary cessation.

Cortisol monitoring matters less with this specific blend. Ipamorelin was designed specifically to avoid the cortisol spikes seen with earlier ghrelin mimetics. Studies confirm cortisol levels remain within normal circadian ranges even at higher ipamorelin doses. Prolactin elevation is similarly absent. The metabolic surveillance focus stays on glucose handling and lipid panels, which can shift unfavourably if GH exposure stays chronically elevated without cycling breaks.

Dosing Protocols That Support Sustained Use

Standard research dosing for tesamorelin ranges from 1–2mg daily, administered subcutaneously before sleep to align with natural nocturnal GH peaks. Ipamorelin dosing typically runs 200–300mcg per injection, often split into two daily administrations (morning and pre-sleep) to mimic physiological pulsatility. The combination protocol most commonly seen in extended research settings: tesamorelin 1mg + ipamorelin 200mcg nightly, five consecutive days per week.

Starting at lower doses and titrating upward over 2–4 weeks reduces acute side effects (injection site reactions, transient water retention, mild joint discomfort). The titration also allows monitoring of individual GH responsiveness. Some subjects show robust IGF-1 elevation at the lower end of the dosing range and don't require escalation. Monitoring IGF-1 at week 4 guides dose adjustment: target range sits between 200–300 ng/mL for most research contexts, though specific study endpoints vary.

Our experience working with peptide research groups shows that dosing consistency matters more than dose magnitude for long-term outcomes. A researcher using 1mg tesamorelin + 200mcg ipamorelin five nights per week for 16 weeks with proper cycling will see better sustained results than someone running 2mg + 400mcg daily for 12 weeks straight. The latter hits receptor fatigue faster and shows steeper IGF-1 decline in the second and third month.

Tesamorelin + Ipamorelin vs Other GH Protocols: Research Context Comparison

Tesamorelin + Ipamorelin Blend

Dual-pathway GHRH + ghrelin receptor activation

12–24 weeks with breaks

5 on/2 off weekly + 4-week breaks every 12–16 weeks

Moderate glucose impact; monitor HbA1c and fasting glucose

Best long-term safety profile among peptide GH protocols when cycled properly. Synergistic effect reduces individual peptide doses needed

CJC-1295 (DAC) + Ipamorelin

Long-acting GHRH analog + ghrelin agonist

8–16 weeks

Less frequent due to DAC extended half-life

Similar glucose concerns; DAC formulation complicates washout

DAC half-life (6–8 days) makes precise cycling harder. Tesamorelin's shorter half-life offers better control

MK-677 (Ibutamoren) Monotherapy

Oral ghrelin mimetic

Continuous use common in research

Rarely cycled in practice

Significant appetite increase; water retention; glucose elevation common

Convenience of oral dosing traded for less precise GH pulsatility and higher metabolic side effect rate

Exogenous rhGH Injection

Direct GH replacement

Variable; often 6+ months

Not typically cycled

Substantial insulin resistance risk; lipid changes; requires close endocrine monitoring

Gold standard for GH deficiency but carries highest metabolic risk and cost. Peptides offer safer long-term alternative for non-deficiency research

The tesamorelin + ipamorelin combination sits in a unique position: it preserves pulsatile GH release (mimicking natural physiology better than constant rhGH), avoids the cortisol and prolactin elevation of older secretagogues, and offers dosing flexibility that long-acting peptides like CJC-DAC don't provide. The trade-off is injection frequency and the discipline required to maintain proper cycling.

Key Takeaways

Tesamorelin + ipamorelin blend demonstrates acceptable long-term safety in research settings when protocols include 5-on-2-off weekly cycling and 4-week breaks every 12–16 weeks to prevent pituitary receptor desensitisation.

GHRH receptor density decreases measurably after 8–12 weeks of continuous daily stimulation without rest intervals, leading to diminished IGF-1 response and reduced protocol efficacy over time.

Glucose metabolism monitoring is essential. Clinical trials show fasting glucose increases of 4–6 mg/dL and HbA1c elevations of 0.2–0.4% with sustained tesamorelin use at 2mg daily for 26 weeks.

Standard research dosing combines tesamorelin 1–2mg with ipamorelin 200–300mcg nightly, with titration over 2–4 weeks reducing acute side effects while allowing individualised IGF-1 response assessment.

Cycled protocols maintain 85–92% of initial IGF-1 elevation through 24 weeks, while continuous-use groups show decline to 60–70% by week 20 due to receptor adaptation.

What If: Tesamorelin + Ipamorelin Scenarios

What If I Run the Blend Continuously for 6 Months Without Cycling?

You'll likely see diminishing returns after week 12–16 as GHRH receptors downregulate under constant stimulation. IGF-1 levels plateau or decline despite continued dosing, body composition improvements stall, and you've spent months on a protocol operating at reduced efficacy. The metabolic load (insulin resistance, elevated fasting glucose) continues accumulating while the benefits fade. Worst of both worlds.

What If My IGF-1 Levels Don't Elevate as Expected in the First Month?

Check injection technique first. Subcutaneous administration depth and timing relative to meals both affect absorption and GH pulse amplitude. If technique is sound, consider dose titration: some individuals are low responders at 1mg tesamorelin and require 1.5–2mg for meaningful IGF-1 elevation. Verify peptide reconstitution and storage (bacteriostatic water, refrigerated at 2–8°C, used within 28 days). Degraded peptides show dramatically reduced potency with no visual indication.

What If I Experience Joint Discomfort or Fluid Retention in Week 2–3?

These are common adaptation responses to elevated GH. Mild joint stiffness and transient water retention occur in 15–25% of research subjects during initial titration. Symptoms typically resolve within 2–3 weeks as the body adjusts to new IGF-1 levels. Reducing dose temporarily (e.g., dropping from 2mg to 1mg tesamorelin for one week) while maintaining the protocol often eliminates discomfort without stopping progress. Persistent or worsening symptoms warrant protocol pause and medical consultation.

What If Blood Glucose Starts Creeping Up After 12 Weeks?

This signals insulin resistance developing under sustained GH elevation. Exactly the metabolic shift that makes cycling essential. Implement a 4-week washout immediately, during which fasting glucose and HbA1c should normalise. When resuming, consider lower dosing (1mg tesamorelin instead of 2mg) or stricter 5-on-2-off adherence. Adding metformin or berberine during peptide phases can blunt glucose elevation in research contexts where metabolic support is protocol-appropriate.

The Blunt Truth About Tesamorelin + Ipamorelin Long-Term Use

Here's the honest answer: tesamorelin + ipamorelin blend is not a 'set it and forget it' protocol. Treating it like a daily multivitamin. Dosing continuously for months without monitoring or cycling. Wastes money and increases metabolic risk while delivering progressively weaker results. The researchers who see sustained benefits over 6–12 months are the ones tracking IGF-1 quarterly, cycling rigorously, and pulling back the moment glucose markers shift unfavourably.

The peptide industry has created an expectation that 'bioidentical' compounds are inherently safe for indefinite use. That's marketing, not physiology. Your pituitary gland has a finite number of GHRH receptors, and overstimulating them without recovery intervals causes measurable desensitisation. This isn't theoretical, it's documented in peer-reviewed endocrinology research. The blend is safer than exogenous rhGH and more controllable than long-acting peptides, but it still requires discipline.

If you're not prepared to cycle, monitor blood work, and adjust dosing based on IGF-1 response, you're better off not starting. A well-executed 16-week cycled protocol produces more meaningful, sustainable body composition changes than 6 months of continuous use with no oversight.

The tesamorelin + ipamorelin blend represents one of the most sophisticated tools in research peptide protocols. Dual-pathway GH stimulation without the cortisol spikes of earlier secretagogues, better pulsatility preservation than exogenous GH, and dosing flexibility that long-acting analogs can't match. Long-term safety isn't a yes-or-no question. It's a function of protocol design. Proper cycling, glucose monitoring, and IGF-1 tracking turn this combination into a viable extended-use research tool. Skipping those steps turns it into an expensive experiment in diminishing returns.

Frequently Asked Questions

Research protocols typically run 12–24 weeks with structured cycling: 5 consecutive days on, 2 days off weekly, plus mandatory 4-week breaks every 12–16 weeks. This cycling schedule prevents pituitary receptor desensitisation and maintains IGF-1 response over extended timelines. Continuous daily use beyond 16 weeks without breaks significantly increases risk of receptor downregulation and metabolic side effects including elevated fasting glucose and reduced protocol efficacy.

Essential monitoring includes IGF-1 levels (baseline, week 4, then every 8 weeks), fasting glucose and HbA1c (baseline, week 8, week 16), and comprehensive metabolic panel tracking liver enzymes and kidney function. IGF-1 should stay between 200–300 ng/mL in most research contexts; declining levels signal receptor desensitisation requiring dose adjustment or cycling break. HbA1c elevation above 5.7% or fasting glucose consistently above 100 mg/dL warrants immediate protocol review.

No evidence supports permanent suppression when protocols include proper cycling. The pituitary downregulation observed with continuous use is adaptive, not structural — receptor density and GH pulsatility return to baseline within 4–8 weeks after cessation in published research. The key is avoiding continuous daily stimulation beyond 16 weeks; cycled protocols with regular breaks allow the pituitary to restore normal function between stimulation phases.

Tesamorelin + ipamorelin offers better long-term metabolic safety due to preserved pulsatile GH release and lower appetite stimulation. MK-677 (ibutamoren) causes continuous GH elevation and significant ghrelin-mediated appetite increase, leading to higher rates of glucose intolerance and water retention in extended protocols. The injectable peptide combination requires more discipline (daily injections, cycling) but produces fewer metabolic side effects when managed properly.

Missing 2–3 days within a week won’t significantly impact results — the 5-on-2-off cycling structure already incorporates regular breaks. Missing an entire week or more causes IGF-1 levels to drop toward baseline, requiring 7–10 days of resumed dosing to re-establish peak levels. Don’t double-dose to ‘catch up’ — resume the standard protocol and accept the temporary dip. Frequent inconsistent dosing undermines the pulsatile stimulation pattern that makes the combination effective.

Caution is warranted — growth hormone induces insulin resistance as part of its metabolic mechanism, and individuals with baseline HbA1c of 5.7–6.4% face higher risk of crossing into diabetic range under sustained GH elevation. Research protocols in this population require more frequent glucose monitoring (every 4 weeks minimum), lower starting doses (1mg tesamorelin instead of 2mg), and often concurrent metformin or berberine to blunt glucose excursions. Medical oversight is essential.

Complete cessation during 4-week breaks is more effective for receptor recovery than dose reduction. Dropping from 2mg to 1mg tesamorelin maintains some GHRH receptor stimulation, slowing the density restoration that cycling aims to achieve. The exception: if acute side effects emerge mid-protocol, temporary dose reduction (while maintaining injection frequency) can resolve symptoms without full protocol interruption. For planned cycling breaks, stop completely to maximise receptor sensitivity reset.

Nighttime injection 30–60 minutes before sleep aligns with natural nocturnal GH peaks and maximises pulsatile release amplitude. Some research protocols split ipamorelin into morning and evening doses (100–150mcg each) to maintain more consistent daily GH elevation, while administering tesamorelin only at night. Single nightly dosing (both peptides together) is simpler and shows comparable IGF-1 elevation in most subjects, making it the standard for long-term adherence.

Stacking additional GH-influencing peptides (CJC-1295, hexarelin, GHRP-2) increases receptor overstimulation risk and complicates monitoring — avoid combination unless research protocol specifically justifies it. Non-GH peptides like BPC-157 or thymosin beta-4 can be run concurrently without direct receptor conflict, though total injection burden and cumulative metabolic load still require consideration. Simpler protocols with fewer variables produce more interpretable long-term results.

IGF-1 begins declining within 48–72 hours of final injection and typically returns to baseline within 10–14 days. This rapid washout is why cycling breaks work — the pituitary isn’t under continuous stimulation pressure during off-weeks, allowing receptor density recovery. The fast clearance also means restarting after a 4-week break requires the same 7–10 day ramp-up period to re-establish peak IGF-1 levels as initial protocol start.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Reconstitution, Dosing, and Stability Parameters for Research Applications

Reconstitution technique determines whether lyophilized peptides retain full bioactivity or degrade before the first injection. Tesamorelin and ipamorelin arrive as sterile, white-to-off-white lyophilized powders in sealed glass vials, typically packaged at 2mg, 5mg, or 10mg per vial. The lyophilization process removes water under vacuum, leaving the peptide in a crystalline or amorphous solid state that remains stable at −20°C for 24–36 months when sealed. Once reconstituted, stability collapses. Reconstituted peptide solutions must be used within 28 days when stored at 2–8°C, and degradation accelerates rapidly at room temperature. The reconstitution solvent matters. Bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) is the standard solvent for multi-dose peptide vials because benzyl alcohol inhibits bacterial growth, allowing repeated needle entries over several weeks without contamination. Sterile water for injection can be used for single-dose applications but offers no antimicrobial protection. Any vial accessed more than once risks bacterial colonization. The reconstitution volume determines final peptide concentration: adding 2mL of bacteriostatic water to a 5mg vial produces a 2.5mg/mL solution, meaning each 0.2mL (20-unit) injection delivers 500mcg. The injection technique most researchers overlook is pressure equilibration. Each time you withdraw solution from a sealed vial, you create negative pressure inside. If you don't replace that volu…
STORAGE

Storage, Stability, and Reconstitution Constraints

Temperature excursions denature peptide structure irreversibly. Unreconstituted lyophilised Tesamorelin + Ipamorelin blends remain stable at −20°C for 24–36 months when stored in the original sealed vial. Once reconstituted with bacteriostatic water, the stability window compresses dramatically: refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C for more than 2 hours causes measurable degradation. The peptide bonds in both Tesamorelin and Ipamorelin are temperature-sensitive, and even brief exposure to room temperature (20–25°C) begins the denaturation cascade. The mistake most researchers make is assuming bacteriostatic water's antimicrobial properties extend peptide stability indefinitely. Bacteriostatic water prevents bacterial growth, but it does nothing to prevent peptide oxidation, aggregation, or hydrolysis. All of which accelerate at temperatures above 8°C. A vial left on the counter for 6 hours while you prepare other materials isn't contaminated, but it is partially denatured. The GH-releasing potency drops by an estimated 15–30% for every 24-hour period spent outside refrigeration, even if no visible cloudiness appears. Light exposure accelerates oxidative degradation. Store reconstituted vials in the original amber glass or wrap them in aluminum foil if transferred to a clear vial. UV light and even ambient室内 lighting trigger oxidative reactions that break peptide bonds. Particularly the methionine and cysteine residues in Tesamoreli…
02

Question drills

Open a question for its connected answer.

01What If I Experience Persistent Water Retention After Two Weeks at 500mcg Per Compound?+

Reduce the dose to 350mcg per compound for one week, then reassess. Water retention is the most common dose-limiting side effect in peptide GH protocols. It occurs because supraphysiological GH pulses increase renal sodium reabsorption and stimulate aldosterone secretion, both of which promote fluid retention. Most cases resolve within 3–4 weeks as the kidneys adapt to the elevated GH environment, but persistent edema beyond two weeks at 500mcg per compound indicates the dose exceeds your individual tolerance threshold.

SOURCE / realpeptides.co ↗
02What If My Fasting Glucose Increases During the Protocol?+

GH has direct insulin-antagonistic effects, particularly when administered without concurrent carbohydrate intake. If fasting glucose rises above 100 mg/dL or HbA1c increases by more than 0.3%, adjust injection timing to post-prandial windows (60–90 minutes after a meal containing protein and moderate carbohydrate). This allows insulin secretion to counterbalance GH's glucose-raising effect. Alternatively, reduce tesamorelin frequency to 5 days per week instead of 7, creating intermittent GH exposure that prevents chronic receptor desensitization. Metformin (if prescribed by a clinician) can mitigate GH-induced insulin resistance in research settings, but dietary adjustment—reducing fructose intake, increasing fiber—should be the first intervention.

SOURCE / realpeptides.co ↗
03What If I Experience Persistent Injection Site Reactions?+

Rotate injection sites consistently (minimum 2 cm from previous injection, alternating left and right lower abdomen) and ensure the peptide solution is at room temperature before injecting. Cold injections increase localized inflammation. If erythema, swelling, or tenderness persists beyond 48 hours at multiple sites, the reaction may indicate sensitivity to benzyl alcohol (the preservative in bacteriostatic water). Switch to sterile water for reconstitution, though this reduces shelf life to 72 hours refrigerated. Persistent reactions also occur with peptides reconstituted at concentrations higher than 1mg/mL for tesamorelin or 2.5mg/mL for ipamorelin. Verify your dilution ratios.

SOURCE / realpeptides.co ↗
04What If Reconstituted Peptide Solution Appears Cloudy or Contains Visible Particles?+

Discard immediately—cloudiness or particulate matter indicates protein aggregation, microbial contamination, or excipient precipitation, all of which render the solution unsuitable for research use. Properly reconstituted tesamorelin and ipamorelin solutions are crystal-clear and colorless. Aggregation occurs when peptides are reconstituted with incorrect diluent (sterile water instead of bacteriostatic water), when the vial is shaken rather than gently swirled, or when the solution undergoes freeze-thaw cycles. Once aggregation begins, it cannot be reversed—the peptide chains have misfolded and lost bioactivity. Real Peptides provides Bacteriostatic Water formulated specifically for peptide reconstitution, with benzyl alcohol preservative at concentrations that prevent bacterial growth without destabilizing peptide structure.

SOURCE / realpeptides.co ↗
05What If the Solution Appears Cloudy or Contains Visible Particles?+

Discard it immediately. Cloudiness or particulate matter indicates aggregation or contamination. Both of which render the solution unsuitable for use. Aggregated peptides lose biological activity and cannot be reversed through filtration or re-refrigeration. Contamination introduces bacterial growth risk that compromises sterility. Clear solutions can still contain submicroscopic aggregates or degradation byproducts, but visible signs are absolute disqualifiers. Never attempt to filter or "salvage" a cloudy peptide solution.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Tesamorelin/Ipamorelin Blend (Tesamorelin, Ipamorelin) Research References

It is a phase 3 compound Tesamorelin/Ipamorelin Blend (Tesamorelin, Ipamorelin) is a phase 3 compound Tesamorelin (Egrifta) approved for reduction of excess abdominal fat in HIV patients. n.d. Tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles. Ipamorelin selectively releases GH without affecting cortisol, prolactin, or ACTH. Combining GHRH and GHRP pathways produces synergistic GH release greater than either alone.

RESEARCH

Standard Concentration Ranges for Tesamorelin + Ipamorelin Research Blends

Commercial research-grade tesamorelin + ipamorelin blends are supplied as lyophilised (freeze-dried) powder in vials containing 5mg, 10mg, or 15mg total peptide mass. The blend ratio varies by supplier. Real Peptides formulates precise ratios based on synergistic growth hormone release kinetics, typically 2:1 or 1:1 tesamorelin to ipamorelin by mass. The concentration you achieve depends on how much bacteriostatic water you add during reconstitution. A 10mg vial reconstituted with 2mL bacteriostatic water yields 5mg/mL. The same vial reconstituted with 4mL yields 2.5mg/mL. Most research protocols target 200–500mcg total peptide per injection (combining both tesamorelin and ipamorelin mass), administered subcutaneously once daily or 5 days per week. At 5mg/mL concentration, a 300mcg dose requires just 0.06mL (60 units on a U-100 insulin syringe). Manageable for small animal models. At 2.5mg/mL, the same dose requires 0.12mL, which is still practical but approaches the upper limit for subcutaneous bolus injection without causing injection-site irritation. The concentration ceiling isn't arbitrary. Published stability data from peptide manufacturers shows aggregation kinetics accelerate non-linearly above 5mg/mL. At 7mg/mL, tesamorelin exhibits visible precipitation within 14 days even under refrigeration. Once you see cloudiness or particulates, the vial is unusable. Ipamorelin is slightly more stable but still shows measurable potency loss above 6mg/mL after 21 days. The 2.5–5mg/mL range represents the empirically validated sweet spot where both peptides maintain structural integrity across a full 28-day use window.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles